<DOC>
	<DOCNO>NCT01744340</DOCNO>
	<brief_summary>The purpose study determine full dose eribulin mesylate safely give full dose cetuximab . The activity combination eribulin mesylate cetuximab recurrent head neck cancer colon cancer also assess .</brief_summary>
	<brief_title>A Dose Finding Study Eribulin Mesylate Cetuximab For Patients With Advanced Head Neck Colon Cancer</brief_title>
	<detailed_description>To determine eribulin mesylate , maximum dose 1.4 mg/m2 day 1 8 21 day cycle , safely combine full dose cetuximab patient advanced head neck cancer colon cancer</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Inclusion Criteria Histologically cytologically confirm advanced squamous cell cancer head neck progression least one prior therapy . ( Chemoradiation consider one line therapy ) . Patients unknown Head Neck primary also eligible In dose escalation cohort , patient advance colon adenocarcinoma wildtype kras previously receive least two line therapy advance disease eligible No longer applicable post February 2013 patient enrol dose escalation phase In expansion phase patient advance colorectal cancer , patient mutate kras previously receive least two line therapy metastatic disease eligible . Pathology report diagnosis report document KRAS status send BrUOG . No longer applicable phase study close 5/6/2014 secondary lack efficacy activity single agent . Life expectancy least 3 month Patients must age 18 year old Patients measurable tumor accord RECIST . Patients must Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 No severe concurrent illness would interfere protocol therapy . Patients must adequate renal function evidence ≤1.5 mg/dL creatinine clearance &gt; 40 mL/minute ( min ) . Patients must adequate bone marrow function evidence absolute neutrophil count ( ANC ) &gt; 1.5 x 109/L platelet count &gt; 100 x 109/L . Patients must adequate hepatic function evidence bilirubin ≤ 1.5 time upper limit normal ( ULN ) alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) ≤ 3 x ULN ( case liver metastases ALT AST ≤ 5 x ULN ) . Resolution chemotherapy radiationrelated toxicity Grade 1 severity , except alopecia . Patients must willing able comply study protocol duration study . Patients must give write informed consent prior studyspecific screening procedure understand patient may withdraw consent time without prejudice . No active invasive malignancy unless disease free least 2 year . Exclusion Criteria For Head Neck patient , progression receive EGFR inhibitor within 6 month stop treatment EGFR inhibitor . Patients receive chemotherapy investigational therapy within 3 week treatment initiation . Radiation must complete within 2 week treatment initiation . Patients hypersensitivity halichondrin B and/or halichondrin B chemical derivative . Patients participate prior eribulin mesylate clinical trial , whether receive eribulin mesylate . Patients significant disease disorder , investigator 's opinion , would exclude patient study . Women pregnant breastfeeding ; woman childbearing potential either positive pregnancy test screening pregnancy test ; woman childbearing potential unless ( 1 ) surgically sterile ( 2 ) use adequate measure contraception opinion Investigator . Perimenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Patients brain subdural metastasis eligible , unless complete local therapy discontinue use corticosteroid indication least 4 week start treatment study . Any sign ( e.g. , radiologic ) and/or symptom brain metastasis must stable least 4 week . Grade 2 bad neuropathy . Significant cardiovascular impairment ( history congestive heart failure &gt; NYHA G II , unstable angina myocardial infarction within past six month , serious cardiac arrhythmia . QTc &gt; 500 msec</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Head Neck</keyword>
	<keyword>Colon</keyword>
</DOC>